Nykode Therapeutics (Vaccibody) småprat (NYKD)

[oscillator]

Hvor ser du det?

[Fornybar]

Som betalende medlem av forumet kan du få daglig oversikt over nesten alle handler i de norske aksjene, med de forsinkelsene som gjelder. I tillegg til å kunne følge bjellesauene støtter du også at selve forumet fortsetter å eksistere.

[Fartin]

Moderna har fått godkjent en oppdatert cpvid vaksine for nye varianter . Nykode har ikke fått ut noe som helst enda. Leit at det tar såpass tid

[TekBot]

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Oslo, Norway, August 22, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET.

A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website: Financial reports and presentations - Nykode.
…

Vis børsmeldingen

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Contact for Nykode Therapeutics ASA:
Chief Business Officer & Investor Relations, Agnete Fredriksen
Nykode Therapeutics AS
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[Dexsign]

Nykode Therapeutics styrket i troen

[TekBot]

Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider

Oslo, Norway, August 26, 2022 - Radforsk Investeringsstiftelse, a legal person closely associated with a primary insider of Nykode Therapeutics ASA has notified the company of a pledge of shares in Nykode Therapeutics ASA.

Please refer to the attached for further information.
…

Vis børsmeldingen

This information made public by Nykode Therapeutics ASA pursuant to article 19 of the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

Kilde

[polygon]

Radforsk bruker aksjer i de børsnoterte selskapene som sikkerhet for å stille med finansiering til andre selskaper og prosjekter. Dette er helt udramatisk (og noe jeg ikke forstår at man ikke skriver i meldingen!).

[Roc]

Noen som har forventet milepælsplanen for Nykode eller? Når kan man forvente nye data og nyheter?

[Fornybar]

[Roc]

Takk! Spennende, så en klinisk readout før nyttår da.

På de interne programmene så er det ikke angitt noe tidspunkt

[Dexsign]

https://finansavisen.no/nyheter/bors/2022/09/05/7924734/dnb-disse-aksjene-gar-inn-og-ut-av-hovedindeksen

[h3nk1]

Hvem går inn/ut?

[Dexsign]

I hht til artikkelen går Nykode inn.

[h3nk1]

Det skjønte jeg, var de andre jeg lurte på

[Dexsign]

I tillegg til Vår Energi og Cadeler.

[h3nk1]

Takk - og ut?

[Dexsign]

Ut Aker Carbon Capture, Nordic Nanovector, Gaming Innovation Group og Pexip

[TekBot]

Nykode Therapeutics to be included in the Oslo Børs Benchmark Index (OSEBX) and the Oslo Børs Mutual Fund Index (OSEFX)

Oslo, Norway, September 8, 2022 - Oslo Børs has announced that Nykode Therapeutics ASA (OSE: NYKD) will be included in the Oslo Børs Benchmark Index (OSEBX) and Oslo Børs Mutual Fund Index (OSEFX), effective September 19, 2022.

Link to the release from Oslo Børs: NewsWeb
…

Vis børsmeldingen

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Contact for Nykode Therapeutics ASA:
Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[kreinh]

Scientists find COVID-19 antibodies that can make boosters unnecessary

[Fornybar]

Bertrand Delsuc